YX0798 is a highly potent, selective, and orally effective CDK9 inhibitor for treating aggressive lymphoma.

ABSTRACT:

Abstract

Nongenetic transcription evolution has been increasingly explored and recognized to drive tumor cell progression and therapeutic resistance. As the regulation hub of transcription machinery, cyclin-dependent kinase 9 (CDK9) is the gatekeeper of RNA polymerase II transcription, and CDK9 dysfunction results in transcriptomic reprogramming and tumor cell progression. We recently reported that the heat shock protein 90 (HSP90)-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma (MCL) through transcriptomic reprogramming. We also showed that targeting CDK9 by AZD4573 and enitociclib is a safe and effective treatment in preclinical Mantle Cell Lymphoma (MCL) models, supporting CDK9 as a valid therapeutic target for MCL. However, current CDK9 inhibitors (CDK9is

SUBMITTER: Jiang V 

PROVIDER: S-EPMC12514485 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature